Loading...
Loading...
PLUR| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | -10.6M |
| Gross Profit | 10.7M |
| Operating Expense | 6.1M |
| Operating I/L | -6.0M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.1M |
| Pretax | -5.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -5.7M |
Pluri Inc. is a biotechnology company specializing in placenta-based cell therapy products for treating inflammatory, muscle injuries, and hematologic conditions. Their flagship product, PLX-PAD, is undergoing Phase III clinical trials for muscle recovery post-hip fracture surgery, Phase II trials for COVID-19-associated acute respiratory distress syndrome, and Phase I/II trials for steroid-refractory graft versus host disease. Additionally, they are developing PLX-R18 for incomplete hematopoietic recovery post-hematopoietic cell transplantation and for acute radiation syndrome treatment. The company generates revenue through the development and commercialization of these cell therapy products for various medical conditions.
